Viking Therapeutics, Inc. 8-K

What Happened
Viking Therapeutics, Inc. (VKTX) announced on February 11, 2026 that it issued a press release reporting its financial results for the fourth quarter and full year ended December 31, 2025 and provided a corporate update. The press release was furnished as Exhibit 99.1 to the Form 8‑K filed the same day. The report was signed by Brian Lian, Ph.D., President and Chief Executive Officer.

Key Details

• Filing date: February 11, 2026 (Form 8‑K).
• Period covered: fourth quarter and year ended December 31, 2025.
• Press release: furnished as Exhibit 99.1 to the Form 8‑K.
• Form items reported: Item 2.02 (Results of Operations and Financial Condition) and Item 9.01(d) (Exhibits).

Why It Matters
This filing makes Viking’s latest earnings and corporate update publicly available; investors should review the Exhibit 99.1 press release for specific figures on revenue, expenses, cash position, and any operational or clinical updates. The 8‑K itself signals that material financial results and corporate information were released — important for assessing short‑term financial health, runway, and progress on the company’s programs. For full detail, read the press release (Exhibit 99.1) and Viking’s subsequent SEC filings.